BioPharmSignal logoBioPharmSignal

Biotech News

CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026

CRISPR Therapeutics (CRSP)CRISPR TherapeuticsConference / presentation

-Data presented in a late-breaking presentation at the European Society of Cardiology (ESC) Congress 2026- -Phase 1a clinical data for CTX310 ® continued to demonstrate robust, dose-dependent reductions in circulating ANGPTL3 with a mean reduction from baseline of 79% (maximum 89%), a mean

Related news

CRSPCRISPR Therapeutics2026-09-08 12:30 EST

CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

CRSPCRISPR Therapeutics2026-11-04 14:01 EST

CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition

RHHBYRoche Holdings AG2026-10-23 17:30 EST

Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)

EDITEditas Medicine2026-10-14 13:00 EST

Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference

NTLAIntellia2026-09-04 12:00 EST

Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference

NTLAIntellia2026-10-29 12:00 EST

Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026

VYGRVoyager Therapeutics2026-10-27 12:01 EST

Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026

SRPTSarepta Therapeutics2026-08-31 20:30 EST

Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

CRBUCaribou2026-11-04 14:00 EST

Caribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual Meeting

SRPTSarepta Therapeutics2026-09-30 12:30 EST

Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne

View all latest news

CRISPR Therapeutics

Gene-Based Medicine Platform CRISPR Therapeutics develops gene-edited medicines across hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare disease. Its toolkit includes CRISPR/Cas9, the SyNTase editing platform, lipid-nanoparticle delivery and engineered cell therapies. CASGEVY CASGEVY...

Recent company news

CRSPCRISPR Therapeutics2026-11-04 14:01 EST

CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition

CRSPCRISPR Therapeutics2026-11-02 21:01 EST

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results

CRSPCRISPR Therapeutics2026-11-02 13:00 EST

CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer

CRSPCRISPR Therapeutics2026-10-19 20:05 EST

CRISPR Therapeutics Announces Chief Financial Officer Transition

CRSPCRISPR Therapeutics2026-10-08 12:30 EST

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026

Stock data

Close
48.56 USD
Market cap
5.02B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States